No Data
Australian Ocean Health: 2024 Annual Report Summary
Australian Ocean Health: 2024 Annual Report
Jiangsu Aoyang Health Industry (002172.SZ): A subsidiary plans to invest 35 million yuan to develop the Zhangjiagang Aoyang Geriatric Hospital project.
Gelonghui, April 14 – Jiangsu Aoyang Health Industry (002172.SZ) announced that the company plans to invest 35 million yuan to develop the Jiangsu Aoyang Hospital for Geriatrics project, with its wholly-owned subsidiary Zhangjiagang Aoyang Geriatrics Hospital Co., Ltd. (referred to as "Aoyang Geriatrics Hospital") as the business entity. The project aims to design a secondary specialized hospital for geriatrics, with approximately 105 approved beds planned. Additionally, to undertake the Aoyang Geriatrics Hospital project, it intends to lease the relevant properties from Jiangsu Aoyang Youju Yibai Old-Age Industry Co., Ltd. (referred to as "Youju Yibai") and sign a "Lease Agreement" for the house rental. The rental address is located in Xindong, Zhangjiagang City.
Jiangsu Aoyang Health Industry (002172.SZ): Net income in 2024 is 40.56 million yuan, a year-on-year decrease of 18.36%.
Gelonghui April 14丨Jiangsu Aoyang Health Industry (002172.SZ) announced its annual report for 2024, with revenue of 2 billion yuan, a year-on-year decrease of 7.54%. The net income attributable to the shareholders of the listed company is 40.56 million yuan, a year-on-year decrease of 18.36%. The net income attributable to the shareholders of the listed company, excluding non-recurring gains and losses, is 32.5767 million yuan, a year-on-year increase of 19.35%.
Jiangsu Aoyang Health Industryltd (SZSE:002172) Delivers Shareholders 23% Return Over 1 Year, Surging 18% in the Last Week Alone
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Investors Don't See Light At End Of Jiangsu Aoyang Health Industry Co.ltd.'s (SZSE:002172) Tunnel
